Galera Therapeutics Converts Preferred Stock and Exercises Warrants, Adding Over 84 Million New Shares

summarizeSummary

Galera Therapeutics has converted over 76 million preferred shares and seen 8.4 million warrants exercised, significantly increasing its common share count and confirming substantial dilution.

check_boxKey Events · Financing and Capital Events · GRTX

• Massive Preferred Stock Conversion

  On April 7, 2026, 76,479.175 shares of Series B Non-Voting Convertible Preferred Stock were converted into 76,479,164 shares of common stock. This conversion alone represents a value exceeding the company's current market capitalization.

• Significant Warrant Exercise

  On April 8, 2026, affiliates of Ikarian Capital, LLC exercised pre-funded warrants for 8,488,229 common shares at an exercise price of $0.001 per share, providing approximately $8,488 in proceeds to the company.

• Remaining Convertible Securities

  Following these transactions, 42,839.11 shares of Series B Preferred Stock and pre-funded warrants to purchase an additional 14,552,811 common shares remain outstanding, indicating further potential dilution.

auto_awesomeAnalysis · GRTX · Life Sciences

This 8-K confirms significant dilution events for Galera Therapeutics, directly impacting its capital structure. The conversion of Series B Preferred Stock into over 76 million common shares, combined with the exercise of pre-funded warrants for an additional 8.4 million shares, represents a substantial increase in the outstanding common stock. This realization of previously disclosed potential dilution comes after the company reported a going concern warning in its recent 10-K, highlighting the ongoing challenges in its financial stability and the cost of its financing arrangements. The cash proceeds from the warrant exercise are minimal compared to the dilutive impact.